Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

This study is for adults, aged 18 and over, who have a diagnosis of chondrosarcoma. Your cancer should either be advanced (meaning it has spread) or not operable, and it must have a specific genetic change called an IDH1 mutation. This mutation will be checked with a special test during the study screening process.

Your cancer also needs to have shown some growth or come back recently, as confirmed by scans. You might have received either no previous systemic treatment (like chemotherapy or immunotherapy) for your advanced cancer, or just one type of systemic treatment. You should generally be well enough to take oral medication and have recovered from any major effects of previous treatments like surgery or radiotherapy.

However, you cannot join this study if you are pregnant or breastfeeding, if you are already taking part in another drug trial, or if you have previously had a medicine that specifically targets the IDH1 mutation. Also, you must be able to swallow pills.

If you join this study, you will be randomly assigned, like flipping a coin, to receive either ivosidenib or a matching placebo (a dummy pill). You will take one pill by mouth once a day. The study involves regular visits to the clinic for assessments, which will include physical examinations, blood tests, and scans (like CT or MRI) to check on your cancer. These scans will help doctors see if the treatment is working and if your cancer is growing or shrinking. The specific schedule of visits and tests will be provided by the study team, but typically involves more frequent visits at the beginning, becoming less frequent over time. You will continue treatment and follow-up for as long as the treatment is benefiting you, or until you experience unacceptable side effects or choose to stop.